As Alnylam Pharmaceuticals (ALNY) Valuation Rose, Rhenman & Partners Asset Management Ab Has Trimmed Position; Facebook (FB) Holding Maintained by Advantus Capital Management Inc

February 15, 2018 - By Winifred Garcia

Advantus Capital Management Inc increased its stake in Facebook Inc (FB) by 0.94% based on its latest 2017Q3 regulatory filing with the SEC. Advantus Capital Management Inc bought 2,246 shares as the company’s stock rose 10.88% with the market. The institutional investor held 240,798 shares of the technology company at the end of 2017Q3, valued at $41.15M, up from 238,552 at the end of the previous reported quarter. Advantus Capital Management Inc who had been investing in Facebook Inc for a number of months, seems to be bullish on the $519.98B market cap company. The stock decreased 0.29% or $0.53 during the last trading session, reaching $178.99. About 14.55M shares traded. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since February 15, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Rhenman & Partners Asset Management Ab decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 46.64% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 37,397 shares as the company’s stock rose 48.45% with the market. The institutional investor held 42,793 shares of the health care company at the end of 2017Q3, valued at $5.03 million, down from 80,190 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $11.96B market cap company. The stock decreased 0.01% or $0.01 during the last trading session, reaching $119.97. About 299,663 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 15, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $783.34 million US Long portfolio, upped its stake in Alkermes Plc (NASDAQ:ALKS) by 9,591 shares to 145,000 shares, valued at $7.37M in 2017Q3, according to the filing. It also increased its holding in Amerisourcebergen Corp (NYSE:ABC) by 35,000 shares in the quarter, for a total of 80,000 shares, and has risen its stake in Nektar Therapeutics (NASDAQ:NKTR).

Since September 20, 2017, it had 0 insider purchases, and 3 insider sales for $23.18 million activity. Greene Barry E sold $10.66 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, October 2.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 96 analyst reports since August 7, 2015 according to SRatingsIntel. On Monday, June 12 the stock rating was maintained by Chardan Capital Markets with “Buy”. The rating was maintained by Goldman Sachs on Thursday, October 6 with “Neutral”. The firm has “Buy” rating given on Friday, July 7 by Chardan Capital Markets. The firm has “Outperform” rating by Credit Suisse given on Wednesday, January 20. The firm earned “Outperform” rating on Thursday, October 6 by Credit Suisse. The stock has “Buy” rating by Jefferies on Monday, September 25. The firm earned “Buy” rating on Friday, November 17 by Piper Jaffray. The firm earned “Outperform” rating on Friday, November 3 by Credit Suisse. The rating was maintained by Cowen & Co on Thursday, September 21 with “Buy”. The firm has “Hold” rating given on Saturday, August 22 by TheStreet.

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.60, from 1.52 in 2017Q2. It turned negative, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Td Asset reported 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blue Ridge Cap Ltd accumulated 1.53M shares. Pnc Fin Group reported 0% stake. Us State Bank De, Minnesota-based fund reported 463 shares. Moreover, Royal Savings Bank Of Canada has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1,763 shares. Moreover, Plante Moran Financial Advisors Ltd has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alliancebernstein Ltd Partnership holds 43,773 shares or 0% of its portfolio. The Kansas-based Kornitzer Cap Mgmt Inc Ks has invested 0.33% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Van Eck Associates Corporation invested in 0.09% or 155,185 shares. Winslow Evans & Crocker invested in 0.05% or 1,400 shares. Moreover, Amundi Pioneer Asset has 0.04% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 95,572 shares. Ww Asset has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Segall Bryant Hamill Ltd Liability Com has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Zurcher Kantonalbank (Zurich Cantonalbank) owns 5,212 shares or 0.01% of their US portfolio. Moreover, Millennium Management Ltd Liability Co has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Advantus Capital Management Inc, which manages about $27.77B and $3.85B US Long portfolio, decreased its stake in Cyrusone Inc (NASDAQ:CONE) by 64,678 shares to 271,191 shares, valued at $15.98 million in 2017Q3, according to the filing. It also reduced its holding in Boston Properties Inc (NYSE:BXP) by 61,974 shares in the quarter, leaving it with 95,693 shares, and cut its stake in Ggp Inc.

Among 54 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 236 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, November 2 by J.P. Morgan. The rating was maintained by RBC Capital Markets with “Buy” on Friday, January 12. The stock of Facebook, Inc. (NASDAQ:FB) has “Sell” rating given on Friday, October 30 by Jyske Bank. As per Thursday, November 3, the company rating was downgraded by BTIG Research. The stock has “Buy” rating by M Partners on Monday, July 17. As per Thursday, November 5, the company rating was maintained by Oppenheimer. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Wednesday, September 27 by Cowen & Co. Needham maintained Facebook, Inc. (NASDAQ:FB) on Wednesday, July 19 with “Buy” rating. Loop Capital initiated the shares of FB in report on Friday, September 23 with “Buy” rating. The stock of Facebook, Inc. (NASDAQ:FB) earned “Overweight” rating by JP Morgan on Tuesday, September 27.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>